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Abstract  
Current methods for assembling biosynthetic pathways in microorganisms require a process of 
repeated trial and error and have long design-build-test cycles. We describe the use of a cell-free 
transcription-translation (TX-TL) system as a biomolecular breadboard for the rapid engineering 
of the 1,4-butanediol (BDO) pathway. We demonstrate the reliability of TX-TL as a platform for 
engineering biological systems by undertaking a careful characterization of its transcription and 
translation capabilities and provide a detailed analysis of its metabolic output. Using TX-TL to 
survey the design space of the BDO pathway enables rapid tuning of pathway enzyme expression 
levels for improved product yield. Leveraging TX-TL to screen enzyme variants for improved 
catalytic activity accelerates design iterations that can be directly applied to in vivo strain 
development. 
 
Introduction 
Utilizing fast-growing microorganisms to produce molecules of industrial relevance has the 
potential to rapidly advance the progress of green chemistry. Processes of traditional chemical 
synthesis require heavy metal catalysts, toxic solvents, and fossil fuels as feedstocks. The 
biosynthetic approach, which uses naturally occurring enzymes, less energy, and renewable 
feedstocks, is becoming an attractive alternative.1-2 However, biosynthetic approaches are 
challenged by long design-build-test cycles. Microbial pathway engineering often has about one-
week cycle time.3 The performance of the pathway is frequently far from design, requiring many 
iterations.4 For example, it took DuPont and Genencor more than 100 person-years of work to 
develop the commercialization of biobased 1,3-propanediol.5 Recent advances in cell-free 
systems offer an alternative to this costly approach. Cell-free systems have been used to reduce 
the cycle time of pathway construction. The design-build-test cycle in a cell-free system using 
linear DNA takes less than one day.6  
 
Cell-free systems simulate a controlled cellular environment that delivers repeatable results. 
Recent research has explored the application of cell-free systems for biological circuits, 
renewable energy, and medicine. The cell-free transcription-translation (TX-TL) system was first 
developed as a biomolecular breadboard to test genetic circuits, and many have been 
demonstrated since.7-10 The synthesis of hydrogen and the development of enzymatic fuel cells in 
cell-free systems has charted new paths for renewable energy.11-12 The high yield of therapeutic 
proteins in E. coli-based cell-free synthesis system also offered new methods for medicinal 
synthesis.13-15 Using cell-free systems for prototyping metabolic pathways is an attractive 
alternative platform for the engineering of biosynthesis in microbial hosts. Lysate of engineered 
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E. coli has been used to support high-level conversion of valuable chemicals,16 and a cell-free 
protein synthesis system has been used to screen enzyme variants.17 Systematic studies of cell-
free systems have monitored the change of pH, measured the change of metabolites over time, 
and evaluated protein synthesis.18-20 Studies have shown that the depletion of ATP is limiting 
near the beginning of a cell-free reaction, and the consumption of glutamate is critical in 
regenerating cofactors.21-23 A correlation between cell-free and in vivo systems has not been 
demonstrated. As such, a systematic side-by-side analysis between in vivo and cell-free systems 
is required for cell-free systems to be considered widely as a prototyping platform for metabolic 
engineering.  
 
Metabolic pathways consist of multiple parts and factors that are combined in precise 
combinations to achieve desired functions. Enzyme expression levels and activity affect target 
product yield. Tuning enzyme expression requires engineering the level of transcription, 
translation, and enzyme activity. Furthermore, balancing expression of multiple genes in parallel 
remains a challenge. Often, enzymes are overexpressed when they are identified to be essential 
for improving target metabolite production. Protein overexpression can affect cell growth24 and 
possibly reduce metabolite production.25 Studies have previously demonstrated the feasibility of 
tuning protein expression levels in vivo for improving metabolite productions.26-28 Cell-free TX-
TL system also provides a platform for investigating the correlation between protein expression 
levels and metabolite production. Cell-free TX-TL system allows simultaneous protein 
expression from multiple pieces of DNA, including linear DNA. Such properties can be used to 
verify pathway enzyme expression and activity. Sun et al.’s work has connected protein 
expression level in TX-TL to in vivo systems by comparing the expression strength of different 
promoters.6 This work takes a further step to compare the dynamics of a metabolic pathway in 
TX-TL to in vivo systems by correlating protein expression levels to metabolite production in 
both systems. 
 
This work aims to demonstrate the reduction of traditional metabolic engineering design-build-
test cycles using the 1,4-butanediol (BDO) pathway as a TX-TL prototype. BDO and its 
derivatives are widely used for producing automotive plastics, electronic chemicals, and elastic 
fibers. BDO has a projected global market of $8.96 billion by 2019.29 Historically, BDO has 
been produced from petrochemical feedstocks, but recently a bio-based process was 
commercialized.30 The BDO pathway used for this bioprocess is shown in Figure 1. The 
pathway converts a tricarboxylic acid (TCA) cycle intermediate succinyl-coA to BDO. From top 
to bottom of the pathway schematic, pathway intermediates include succinyl semialdehyde, 4-
hydroxybutyrate (4HB), 4-hydroxybutyryl-coA (4HB-coA), and 4-hydroxybutryaldehyde (4HB-
aldehyde). CoA-dependent succinate semialdehyde dehydrogenase (sucD) catalyzes the 
conversion of succinyl-coA to succinyl semialdehyde. 4- hydroxybutyrate dehydrogenase (4-
hbd) catalyzes succinyl-coA to 4HB. 4-hydroxybutyryl-coA transferase (cat2) catalyzes 4HB to 
4HB-coA. 4-hydroxybutyryl-coA reductase (ald) catalyzes 4HB-coA to 4HB-aldehyde. Alcohol 
dehydrogenase (adh) catalyzes 4HB-aldehyde to BDO. 
 
The main goal of this work is to demonstrate TX-TL as a research tool for metabolic engineering 
and to establish the feasibility of design space exploration (shown in Figure 1). Using the BDO 
pathway previously developed by Genomatica Inc.,31 we add linear DNA encoding pathway 
enzymes to TX-TL. We measure the resulting transcriptional and translational outputs and 
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pathway related metabolites. We also use TX-TL to rapidly tune pathway enzyme expression 
levels for design space exploration of the BDO pathway. Ribosome-binding site (RBS) elements 
of varying strengths are chosen from the bicistronic design (BCD) library to adequately explore 
the design space of the BDO pathway in TX-TL. The two Shine-Dalgarno motifs from BCD 
allows the first one to make a leader peptide to open the second one, which delivers precise and 
reliable translation initiation. The translational coupling architecture BCD ensures protein 
expression at expected levels independent of downstream sequence.32 Through exploring the 
design space of the BDO pathway in TX-TL and in vivo, we systematically compare the 
metabolic output and enzyme expression levels. To show the industrial relevance of TX-TL, we 
demonstrate that the use of linear DNA in TX-TL has the capabilities to serve as a biomolecular 
breadboard to speed up design iterations, and results from TX-TL can be applied to in vivo strain 
development.  
 
Figure 1: TX-TL as a platform for engineering biosynthetic pathways. A design-build-test-learn 
cycle using a BDO pathway previously designed by Genomatica Inc. is shown. Linear DNA that 
encodes pathway enzymes is added to TX-TL. The transcription and translation machinery and 
metabolic output of TX-TL are analyzed. The design space of the BDO pathway is explored in 
TX-TL and in vivo for comparison. Design: Genomatica Inc. previously designed the BDO 
synthesis pathway. Build: Generate linear DNA with sequences of pathway enzymes under the 
same promoters, UTRs, and terminators, subsequently tune enzyme expression levels by varying 
UTR strength, and assemble into plasmids for design space exploration of the BDO pathway. 
Test: The TX-TL system is analyzed systematically and compared to the in vivo system in 
parallel. Learn: Systematic analysis of TX-TL through reverse transcription-PCR (RT-PCR), 
Western blot, and metabolomics. Explore design space: Compare the expression of bottleneck 
enzyme and BDO production in TX-TL and in vivo. 
 
Results and Discussion  
Pathway Verification in TX-TL 
Pathway enzymes are expressed in TX-TL reactions by adding linear DNA. Linear pieces of 
DNA are generated by amplifying regions encoding a promoter, a 5’-untranslated region (UTR), 
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a coding sequence of an individual pathway enzyme, and a terminator. End products of TX-TL 
reactions are directly used for polyacrylamide gel electrophoresis with sodium dodecyl sulfate 
(SDS-PAGE) preparation, and all enzymes of the BDO pathway show up on the gel at expected 
sizes (as shown in Figure S1). By adding linear DNA encoding enzymes from the BDO pathway 
sucD (035), 4hbd (036), cat2 (034), ald (025B), and adh (012), we identify that the conversion 
from 4HB-coA to downstream metabolites is limiting the production of BDO. After 16-hour 
reactions, more than 10 mM of 4HB is detected, and only 0.5 (± 0.1) mM of BDO is detected. 
3.1 (± 0.1) mM of gamma-butyrolactone (GBL) is also detected. GBL is the lactonized form of 
4HB, and it is hypothesized to be produced spontaneously from 4HB-coA via cat2. The 
production of 4HB and GBL suggests that sucD (035), 4hbd (036), and cat2 (034) are not rate-
limiting enzymes for the pathway, and ald (025B) and adh (012) can be rate-limiting. Previous 
results from Yim et al.33 and Barton et al.34 also agree with our observation of such pathway 
dynamics. We, therefore, hypothesize ald and adh as the bottleneck enzymes for the production 
of BDO in TX-TL. To better understand TX-TL as a platform for metabolic engineering, we pick 
a more advanced cat2, ald and adh combination, cat2 (C), ald (C), and adh (C), for studying a 
wider range of system dynamics. During an initial experiment with the advanced enzymes, 3.4 (± 
0.9) mM of BDO is detected, and about 3.2 (± 0.5) mM of GBL is detected.  
The conversion from 4HB to BDO requires the TX-TL system to supplement for electron 
transfer via cofactors. We subsequently test cofactor concentrations for directing metabolic flux 
into the production of BDO. We focus on cofactors directly related to the last three steps of the 
BDO pathway: NADP, NADPH, acetyl-coA, and coA. The absence of acetyl-coA or coA added 
into the TX-TL system results in less BDO, less GBL, but more 4HB. Also, the addition of 
acetyl-coA instead of coA helps produce more GBL, which translates to more 4HB-coA 
synthesized. We hypothesize that the TX-TL system needs more acetyl-coA for the BDO 
pathway. 1 mM of acetyl-coA is added for the rest of the work. The absence of NADP or 
NADPH does not drastically affect target metabolite production, but the addition of NADPH 
improves the production of BDO. 4 mM of NADPH is added for rest of the work, and details can 
be found in Figure S2.  These results suggest that the availability of NADPH in TX-TL is 
limiting the synthesis of downstream products. Such indicates that more strain engineering 
around the TCA cycle or the pentose phosphate pathway (PPP) may help resolve cofactor 
imbalance in TX-TL.   
 
System-level studies in TX-TL 
Results from system-level studies of TX-TL system are shown in Figure 2. For the analysis of 
transcription and translation, we focus on the bottleneck enzyme ald (C). The characterization of 
the transcription and translation of ald (C) are carried out by adding linear DNA encoding 
individual pathway enzymes. We also perform metabolomics on TX-TL reactions to grasp an 
understanding of the metabolic network.  
   
Transcription 
We predict and observe resource limitations of TX-TL by studying the change in mRNA 
expression dynamics based on how much DNA is added to the TX-TL reaction. Figure 2a shows 
the mRNA expression of ald (C) from TX-TL reaction added with just linear DNA encoding ald 
(C) in blue circles. The orange squares show expression of ald (C) from TX-TL reaction added 
with linear DNA encoding individual pathway enzymes. The blue and orange line are the 
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respective predicted mRNA dynamics generated by the TX-TL modeling toolbox.35 The linear 
DNA encoding other pathway enzymes competes with linear DNA encoding ald (C) for 
transcription. The mRNA expression difference of the peak mRNA value is greater than 80%. 
Note that 30 nM of linear DNA encoding ald (C) is added, and a total of 60 nM of linear DNA 
encoding other pathway enzymes is added. The transcription of ald (C) is analyzed using RT-
PCR. The background signal from DNA is subtracted. The mRNA level peaks within the first 
hour and then drops to zero by the end of the first five hours. The rapid degradation of mRNA in 
TX-TL reflects resource limitations of the system. The dynamics of mRNA in TX-TL is similar 
to previously reported.36 
 
Translation 
The expression of ald (C) and adh (C) in TX-TL is analyzed using Western blots and can be 
normalized by total protein intensities measured from SDS-PAGE.37 Complete SDS-PAGE and 
Western blots for the time-course ald (C) expression is shown in Figure S4. Protein degradation 
is observed, which is most likely due to the presence of protease in the extract. Extract used in 
this work is prepared with S138 (MG 1655 △adhE △ldhA △pflB + lpdA*), an engineered E. 
coli strain previously reported.33 Most cell-free systems are either developed with purified 
reagents or with cell lysates from strains with protease deletion. Protein degradation is rarely 
captured. However, protein degradation is expected here because of the lack of protease gene 
knockout. The total and soluble protein expression of ald (C) and adh (C) in TX-TL are shown in 
Figure 2b. Their respective sizes are 60 kDa and 40 kDa. Most of the enzymes remain in the 
soluble fraction of the TX-TL reactions. The amount of each protein band on the ladder is 
approximately 200 ng,38 and the concentration of ald (C) should be on the order of 10 ng/ul.  
 
Metabolomics 
To understand the metabolism in TX-TL, we carry out experiments to collect time-course data of 
metabolites. The production of pathway intermediate 4HB and target metabolite BDO is shown 
in Figure 2c. The production of 4HB peaks around 4 hours into the reaction. The level of 4HB 
drops as the compound is converted to downstream metabolites. The concentration of BDO 
increases as the concentration of 4HB decreases. The concentration of 4HB-coA peaks between 
6 and 8 hours, when BDO concentration starts to plateau, and byproducts GBL starts to 
accumulate (shown in Figure S3d). We hypothesize that the consumption of glutamate links to 
cofactor regeneration. The production of BDO depends on two steps of NADPH-dependent 
electron transfer. The concentration of NADPH drops to the detection limit by the end of the 
fourth hour into the TX-TL reaction. Since NADPH is a critical cofactor for the synthesis of 
BDO, the rate of NADPH being reduced should be the same magnitude as the rate of NADPH 
being oxidized. The ratio of NADPH/NADP is shown in Figure S3b. Carbon flux through the 
TCA cycle is very weak, but the consumption of glutamate is very prominent. In Figure 2d, the 
conversion of glutamate reaches 80% by the end of TX-TL reactions. A preliminary 13C analysis 
also confirms that glutamate consumption is the primary energy source (data not shown). 
Furthermore, the conversion from glutamate to α-ketoglutarate reduces NADP to NADPH. The 
amount of glutamate consumed equals to roughly the sum of 4HB produced, GBL produced, and 
the BDO produced. The consumption of glutamate is the primary metabolic flux in the TX-TL 
system.  
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We learn from the system-level studies that the first few hours are valuable for comparison 
between pathways or enzyme variants. TX-TL is a resource-limited system: mRNA degradation 
starts after the first hour, and protein degradation and cofactor imbalance happens. Metabolic 
flux in TX-TL mainly comes from glutamate, which is also the energy source for regenerating 
cofactors.  
 
Figure 2: System-level studies of TX-TL. a. Transcription: Relative mRNA for ald (C) measured 
using RT-PCR in the first five hours of TX-TL reactions. Blue circles represent data points for 
mRNA expression of ald (C) from TX-TL reaction added with just linear DNA encoding ald (C), 
and orange squares represent data points for mRNA expression of ald (C) from TX-TL reaction 
added with linear DNA encoding all individual pathway enzymes. The blue and orange line 
represents the respective predictive dynamics. b. Translation: Protein expression analyzed using 
Western blotting over a 24-hour time range. The top half shows results from analysis of TX-TL 
reactions, and the bottom half shows results from analysis of supernatant of TX-TL reactions. 
Both were generated from the same blot. c. Metabolite Production: Measured concentrations of 
1,4-BDO (blue circle) and 4HB (red diamond) over time in TX-TL. d. Glutamate Consumption: 
Glutamate consumption over time in TX-TL (blue circle) and conversion (orange square). Error 
bars show one standard deviation for n ≥ 3 independent experiments.  
 
Design space exploration  
The expression levels of ald (C) and adh (C) are modulated to explore the design space of the 
BDO pathway. The expression levels of sucD (035), 4hbd (036), and cat2 (034) are held at fixed 
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levels. The expression levels of all pathway enzymes are adjusted by tuning the UTR. 
Constructing the BDO pathway using parts from the BCD library helps modulate pathway 
enzyme expression levels in TX-TL and in vivo. Details of construct design can be found in 
Figure S5. We generate constructs with varying enzyme expression levels, and the level of 
soluble ald (C) expression in TX-TL and in vivo are shown in Figure 3a and Figure 3d, 
respectively. The SDS-PAGE and Western blot images are shown in Figure S6. BCD 2, BCD 
20, and BCD 22 are used to modify protein expression level to high, medium, and low. We have 
constructed plasmids with ald (C) and adh (C) using a convergent orientation to minimize 
genetic context effects.39 The nine different constructs (shown in Table S1) show a range of 
protein expression levels in TX-TL and in vivo. The ald (C) expression levels are similar in TX-
TL and in vivo. However, the expression of ald (C) with constructs containing BCD 22 show 
higher relative expression in vivo versus in TX-TL.  
 
We examine the effect of the expression level of ald (C) on metabolite production in both 
systems. Although the metabolic output in TX-TL is not exactly the same as the one in vivo, we 
observe that the production of BDO is closely related to the expression level of the bottleneck 
enzyme ald (C) in TX-TL and in vivo, which matches with previous studies.25 The BDO 
production level from the constructs in the two systems is different. Figure 3b and 3e shows the 
production levels of BDO from the designed constructs. The BDO production from constructs 
with strong adh (C) expression are lower in vivo than in TX-TL. As shown in Figure 3b and 3c, 
BDO production level is linearly correlated to ald (C) expression from constructs containing the 
same BCD in front of the adh (C) coding region. Overall, the concentration of BDO produced is 
linearly correlated to the relative expression levels of ald (C) in TX-TL regardless of the 
expression level of adh (C). As shown in Figure 3e and 3f, the concentration of BDO produced 
is linearly correlated to the relative expression levels of ald (C) in vivo for some constructs. The 
expression of adh (C) is overexpressed for constructs containing BCD 2 in front of the coding 
region of adh (C). Protein overexpression seems to cause a metabolic burden so strong with high 
adh (C) expression that the production of BDO is limited to about 1 mM regardless of the 
expression level of ald (C). Data collected from both systems indicates that ald (C) is the 
bottleneck enzyme of the BDO pathway. 
 
Resource limitation is a more prominent problem in vivo versus TX-TL. The in vivo system 
carries a larger metabolic burden with more complicating factors such as cell growth and the 
development of antibiotic resistance. While developing and maintaining the transcription and 
translation machinery, the in vivo system also fights against the antibiotics in the culture broth. 
Although we have used promoter pA40 as part of the constructs, leaky enzyme expression is still 
a problem. Transformation of constructs containing BCD2 (for strong expression) is problematic. 
At 37 °C, the production of BDO in vivo is much lower due to metabolic burden (data not 
shown). At 30 °C, the production of BDO in vivo is comparable to the production of BDO in 
TX-TL. The production level difference can be the supplement of NADPH and acetyl-coA in the 
TX-TL system.    
 
The mapping of design space of metabolic pathway from TX-TL to in vivo can be further tuned 
by repeating the design-build-test cycle shown in Figure 1. There are two ways to map the two 
systems more closely. The first way is to redesign plasmid constructs. Re-constructing the 
pathway with a different set of BCDs, perhaps using BCD 9 or BCD12 instead of BCD 2, can 
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alleviate the metabolic burden in vivo. Using weaker BCDs can potentially avoid overexpression 
enzymes in vivo, which can more effectively show the linear correlation between ald (C) 
expression level and BDO production. The second way is to tune protein expression in TX-TL. 
Plasmid concentration within cells are hard to control, but the expression level of proteins in TX-
TL can be tuned by adjusting the concentration of added DNA.6 In other words, the 
concentration of the added DNA can be adjusted to map protein expression levels in TX-TL to in 
vivo. In this work, we have chosen a relatively low DNA concentration to show a linear range of 
dynamics between ald (C) expression and BDO production. More design iterations will lead to 
better mapping results.   
 
This work has only used batch mode reaction to compare the two systems strictly. However, both 
systems can benefit from pH control by feeding base. Cell growth is limited by pH (shown in 
Figure S9), and the pH can be tuned by adjusting buffer.  
 
 
Figure 3: Design Space Exploration in TX-TL and in vivo. a. Heat map of ald (C) expression in 
TX-TL: Green—ald (C) expression as the RBS strength of the ald (C) varies. b. Heat map of the 
corresponding BDO production in TX-TL: Orange—BDO production (mM) as the RBS strength 
of the ald (C) varies. c. BDO production versus protein expression in TX-TL: blue—strong BCD 
for adh (C), orange—medium BCD for adh (C), green—weak BCD for adh (C), circle: weak 
BCD for ald (C), triangle: medium BCD for ald (C), square: strong BCD for ald (C). d. Heat 
map of ald (C) expression in vivo: Green—ald (C) expression as the RBS strength of the ald (C) 
varies. e. Heat map of the corresponding BDO production in vivo: Orange--BDO production 
(mM) as the RBS strength of the ald (C) varies. f. BDO production versus protein expression in 
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vivo: blue—strong BCD for adh (C), orange—medium BCD for adh (C), green—weak BCD for 
adh (C), circle: weak BCD for ald (C), triangle: medium BCD for ald (C), square: strong BCD 
for ald (C). Error bars show one standard deviation for n ≥ 3 independent experiments. 
 
Application of TX-TL 
We apply the TX-TL system to compare three different enzyme combinations of the BDO 
pathway. The reaction conditions for testing the enzyme combinations are the same. The same 
sucD (035) and 4hbd (036) are added into TX-TL. The three different enzyme combinations are 
A: cat2 (034), ald (025B), and adh (012) previously published,33 B: cat2 (B), ald (B), and adh 
(B) previously published,34 C: evolved version of combination B, cat2 (C), ald (C), adh (C). As 
shown in Figure 4, we study the production of BDO, 4HB, and GBL in TX-TL. Combination C 
results with the greatest BDO production rate, and the production of byproduct GBL is the 
lowest respectively. The production of 4-HB is very similar for all three combinations, but this 
could be the conversion to 4-HB is reaching equilibrium by the end of the TX-TL reaction. Since 
the conversion from glutamate to 4-HB is redox neutral, the accumulated 4-HB is almost the 
same for all three combinations. Enzyme expression comparison between Combination B and 
Combination C is shown in Figure 4b. Notably, the expression of ald and adh in combination B 
is much weaker than the expression of ald and adh in combination C. The engineered enzymes 
from Combination C is evolved for stability and enzyme specificity for NADPH.  
 
Figure 4: Application of TX-TL—pathway ranking. a. BDO production in the first 8 hours of the 
TX-TL reaction is shown. b. Soluble protein in the first 8 hours of the TX-TL reaction is shown. 
c. 4HB production in the first 8 hours of the TX-TL reaction is shown. d. GBL production in the 
first 8 hours of the TX-TL reaction is shown. Blue circle—enzyme combination A, orange 
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circle—enzyme combination B, green square—enzyme combination C. Error bars show one 
standard deviation for n ≥ 3 independent experiments. 
 
Conclusion  
This work shows that TX-TL can be a reliable engineering platform for metabolic engineering. 
Through studying transcription, translation, and metabolism in TX-TL, we find that the 
limitation of the TX-TL system lies within rapid degradation of mRNA and cofactor imbalance. 
The main energy source of TX-TL is glutamate, which is different from the in vivo system but 
this does not impact its ability to produce target metabolites similar to small-scale in vivo 
synthesis. The ease of adding DNA of interests and tuning protein expression by DNA 
concentrations opens up unique opportunities for rapidly exploring pathway design space. 
Studying the BDO pathway in both TX-TL and in vivo helps confirm that TX-TL is a reliable 
tool for capturing pathway dynamics. Successfully demonstrating the viability of transcription 
and translation machinery in S138 extract and the production of BDO provides confidence for 
future prototyping and engineering in extracts made with advanced E. coli strain or potentially 
other organisms.   
 
Materials and Methods  
 
Cultivation 
48-well plates are used for cell culture and metabolite production. M9 minimal salts medium 
(6.78 g l−1 Na2HPO4, 3.0 g l−1 KH2PO4, 0.5 g l−1 NaCl, 1.0 g l−1 NH4Cl, 1 mM MgSO4, 0.1 
mM CaCl2) is used, and it is supplemented with 10 mM NaHCO3, 20 g l−1 D-glucose and 100 
mM MOPS to improve the buffering capacity, 10 µg ml−1 thiamine and the appropriate 
antibiotics. 0.5 mM of IPTG is added to induce enzyme expression. Cell culture starts with 
overnight growth in LB followed by another overnight growth in minimal media and final 
culture. The final culture is placed on a shaker at 650 rpm at 30°C or 37°C for cultivation. The 
culture is centrifuged to collect pellet for protein analysis and supernatant for metabolite 
analysis.  
Cell-Free Expression Preparation and Execution 
Fermentations are performed with 1 L initial culture volume in 2-l Biostat B+ bioreactors 
(Sartorius Stedim Biotech). The temperature is held at 37 °C, and the pH is held at 7.0. Cells are 
grown aerobically to an optical density (O.D.) of approximately 10, at which point the culture 
goes through a series of spin-down, re-suspense, and wash cycle according to protocol described 
by colleagues previously.41 Collected cell pellets are homogenized using M-110F Microfluidizer 
Processor and extracted according to the method described by Kwon et al.42 with the post-
homogenization incubation period extended to 80 min instead of 60 min. Buffer preparation is 
done according to Sun et al.’s protocol41 with a supplement of 30 mM maltodextrin. The 
preparation results in extract with conditions: 8.9−9.9 mg/mL protein, 4.5−10.5 mM Mg-
glutamate, 20-40 mM K-glutamate, 0.33−3.33 mM DTT, 1.5 mM each amino acid except 
leucine, 1.25 mM leucine, 50 mM HEPES, 1.5 mM ATP and GTP, 0.9 mM CTP and UTP, 0.2 
mg/mL tRNA, 0.26 mM CoA, 0.33 mM NAD+, 0.75 mM cAMP, 0.068 mM folinic acid, 1 mM 
spermidine, 30 mM 3-PGA, 4 mM NADPH, 1 mM acetyl-coA, and 1 mM NADH. When 
needed, inducers such as IPTG, linear DNA or plasmid DNA are added to a mix of extract and 
buffer. TX-TL reactions are conducted in PCR tubes and kept at 29°C with incubation in PCR 
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machine. BioTeK Synergy H1 microplate reader is used to collect kinetic data for fluorescent 
protein and MG-Aptamer.  
 
 
 
Plasmid DNA, PCR Product Preparation, and Cloning 
PCR products are amplified using KOD (Novagen, EMD). Plasmids are miniprepped using a 
QIAprep spin columns (Qiagen) and further concentrated with Millipore’s Amicon Ultra-0.5 
Centrifugal Filter Unit with Ultracel-30 membrane. All plasmids are processed at stationery 
phase. Before use in the cell-free reaction, PCR products undergo an additional PCR purification 
step using QIAquick PCR Purification Kit (Qiagen), which removes excess salt detrimental to 
TX-TL and are eluted and stored in water at −20°C for long-term storage. Gibson Assembly 
Ultra and Gibson Assembly HiFi Master Mix from SGI-DNA are used for plasmid assembly.  
 
Analytical Methods  
LCMS/MS is used to analyze TX-TL samples and supernatant of cell culture. TX-TL samples 
were first diluted with 1:3 volume ratio with methanol to remove proteins and other big 
molecules, and then diluted 1: 12.5 with diluent containing labelled internal standards before 
LCMS analysis. Cell culture samples were diluted 1:50 with same diluent before LCMS analysis. 
API3200 triple quadrupole system (AB Sciex, Life Technologies, Carlsbad, CA), interfaced with 
Agilent 1260 HPLC, utilizing electrospray ionization and MRM based acquisition methods is 
used. BDO and GBL are detected using positive ionization mode, while 4HB and related acidic 
compounds are detected using negative ionization mode. Zorbax Eclipse XDB C18 4.6x30mm 
(particle size 1.8um) was used. Column temperature is maintained at 40°C, flow rate of 0.7 
mL/min. Injection volume is 5 ul. Eluents include water with 0.1% formic acid (A) and methanol 
with 0.1% formic acid (B). A fast 1.5 min 5-95% methanol gradient is used, resulting in 1.5 min 
long LCMS method. 
 
Protein Gel and Western blotting 
Culture pellets are resuspended with Novagen BugBuster Protein Extraction solution mixed with 
rLysozyme and benzonase. The amount of BugBuster added is normalized based on the OD 
value of 1mL culture. Samples are incubated at room temperature for 20 minutes. An equal 
volume of 2X Laemlii buffer containing 5% of ß-mercaptoethanol is mixed with each sample. 
The mixture is subsequently boiled in a thermocycler at 99°C for 5 min. 10ul of a mixture 
containing cell pellets is loaded into each lane, or 5 ul of a mixture containing TX-TL sample is 
loaded. Invitrogen MagicMarker XP Western Protein Standard and Bio-Rad Kaleidoscope is 
added as protein ladders. Bio-Rad 4-15% Criterion TGX (Tris-Glycine eXtended) Stain-Free 
precast gels are used. Gel imaging is done using Bio-Rad Gel Doc EZ Imager for measuring total 
protein intensity. Invitrogen iblot system is used for gel transfer. Western blot imaging is done 
using the Chemi Hi Resolution setting on a BioRad ChemiDoc MP imager. The intensity from 
Western blot is normalized by the total protein from each lane, and stain-free total protein is the 
loading control for Western Blots.37 Protein band intensity is determined by using Image Lab 
5.2.1.  
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